header6

Medical Utility

  1. Prediction, diagnosis and monitoring of shock enabling early vasopressor therapy, e.g. in sepsis. Read more…
  2. Prediction, diagnosis and monitoring of (de)congestion in acute heart failure enabling guidance of diuretic treatment. Read more…

sphingotest® bio-ADM Immunoassay

  1. The only available IVD method to measure the amidated bioactive Adrenomedullin (bio-ADM)
  2. The sphingotest® bio-ADM Brochure can be downloaded here

Literature

Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care. 2014; 18(1):R34. PubMed PMID: 24533868.

Self WH, Storrow AB, Hartmann O, Barrett TW, Fermann GJ, Maisel AS, Struck J, Bergmann A, Collins SP. Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. Am J Emerg Med. 2016; 34(2):257-62. PubMed PMID: 26577429.

Yuyun MF, Narayan HK, Quinn PA, Struck J, Bergmann A, Hartmann O, Ng LL. Prognostic value of human mature adrenomedullin in patients with acute myocardial infarction. J Cardiovasc Med (Hagerstown). 2016. 18(1):42-50. PubMed PMID: 26766169.